The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Designing the next generation of medicines for malaria control and eradication
Open accessAbstract
In the fight against malaria new medicines are an essential weapon. For the parts of the world where the current gold standard artemisinin combination therapies are active, significant improvements can still be made: for example combination medicines which allow for single dose regimens, cheaper, safer and more effective medicines, or improved stability under field conditions. For those parts of the world where the existing combinations show less than optimal activity, the priority is to have activity against emerging resistant strains, and other criteria take a secondary role. For new medicines to be optimal in malaria control they must also be able to reduce transmission and prevent relapse of dormant forms: additional constraints on a combination medicine. In the absence of a highly effective vaccine, new medicines are also needed to protect patient populations. In this paper, an outline definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are needed (target candidate profiles) is suggested. In addition, the optimal and minimally acceptable characteristics of combination medicines are outlined (target product profiles). MMV presents now a suggested framework for combining the new candidates to produce the new medicines. Sustained investment over the next decade in discovery and development of new molecules is essential to enable the long-term delivery of the medicines needed to combat malaria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome sequence of the human malaria parasite Plasmodium falciparum
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., et al. (2002) · Nature · doi:10.1038/nature01097 · Cited by 4,407 · cited 1×
“With the sequencing of the parasite genomes [3-5], new potential drug targets have emerged.”
BackgroundWeltgesundheitsorganisation (2005) · Cited by 3,799
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67176-0 · Cited by 1,050
Dondorp, A. M., Fanello, C. I., Hendriksen, I. C., Gomes, E., Seni, A., Chhaganlal, K. D., Bojang, K., Olaosebikan, R., Anunobi, N., Maitland, K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61924-1 · Cited by 1,022
Comparative genomics of the neglected human malaria parasite Plasmodium vivax
Carlton, J. M., Adams, J. H., Silva, J. C., Bidwell, S. L., Lorenzi, H., Caler, E., Crabtree, J., Angiuoli, S. V., Merino, E. F., Amedeo, P., et al. (2008) · Nature · doi:10.1038/nature07327 · Cited by 835
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
A Research Agenda to Underpin Malaria Eradication
Alonso, P. L., Brown, G., Arevalo-Herrera, M., Binka, F., Chitnis, C., Collins, F., Doumbo, O. K., Greenwood, B., Hall, B. F., Levine, M. M., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000406 · Cited by 667
Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L., Nguon, C., Day, N. P. J., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2331 · Cited by 645
The genome of the simian and human malaria parasite Plasmodium knowlesi
Pain, A., Böhme, U., Berry, A. E., Mungall, K., Finn, R. D., Jackson, A. P., Mourier, T., Mistry, J., Pasini, E. M., Aslett, M. A., et al. (2008) · Nature · doi:10.1038/nature07306 · Cited by 384
Moiroux, N., Gomez, M. B., Pennetier, C., Elanga, E., Djènontin, A., Chandre, F., Djègbé, I., Guis, H., & Corbel, V. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis565 · Cited by 383
Delves, M., Plouffe, D., Scheurer, C., Meister, S., Wittlin, S., Winzeler, E. A., Sinden, R. E., & Leroy, D. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001169 · Cited by 377
Charman, S. A., Arbe-Barnes, S., Bathurst, I. C., Brun, R., Campbell, M., Charman, W. N., Chiu, F. C. K., Chollet, J., Craft, J. C., Creek, D. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015762108 · Cited by 373
A Research Agenda for Malaria Eradication: Drugs
The malERA Consultative Group on Drugs (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000402 · Cited by 288
A Research Agenda for Malaria Eradication: Vector Control
The malERA Consultative Group on Vector Control (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000401 · Cited by 273
Knowlesi malaria: newly emergent and of public health importance?
Cox-Singh, J., & Singh, B. (2008) · Trends in Parasitology · doi:10.1016/j.pt.2008.06.001 · Cited by 266
A Research Agenda for Malaria Eradication: Vaccines
The malERA Consultative Group on Vaccines (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000398 · Cited by 264
A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics
The malERA Consultative Group on Diagnoses and Diagnostics (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000396 · Cited by 248
Sanz, L. M., Crespo, B., De-Cózar, C., Ding, X. C., Llergo, J. L., Burrows, J. N., García-Bustos, J. F., & Gamo, F.-J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030949 · Cited by 225
Self-citationErratum: Artemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L., Nguon, C., Day, N. P. J., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2385 · Cited by 222
Bousema, T., Dinglasan, R. R., Morlais, I., Gouagna, L. C., van Warmerdam, T., Awono-Ambene, P. H., Bonnet, S., Diallo, M., Coulibaly, M., Tchuinkam, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042821 · Cited by 210
Jiménez-Díaz, M. B., Mulet, T., Viera, S., Gómez, V., Garuti, H., Ibáñez, J., Alvarez-Doval, A., Shultz, L. D., Martínez, A., Gargallo-Viola, D., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00519-09 · Cited by 187
Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio
Rinaki, E., Valsami, G., & Macheras, P. (2003) · Pharmaceutical Research · doi:10.1023/b:pham.0000008037.57884.11 · Cited by 176
The global pipeline of new medicines for the control and elimination of malaria
Anthony, M. P., Burrows, J. N., Duparc, S., JMoehrle, J., & Wells, T. N. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-316 · Cited by 167
Self-citationAngulo-Barturen, I., Jiménez-Díaz, M. B., Mulet, T., Rullas, J., Herreros, E., Ferrer, S., Jiménez, E., Mendoza, A., Regadera, J., Rosenthal, P. J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002252 · Cited by 163
A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance
The malERA Consultative Group on Monitoring, E. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000400 · Cited by 161
Primaquine in vivax malaria: an update and review on management issues
Fernando, D., Rodrigo, C., & Rajapakse, S. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-351 · Cited by 160
The State of the Art in Anti-Malarial Drug Discovery and Development
Burrows, J. N., Chibale, K., & Wells, T. N. C. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795429194 · Cited by 157
Self-citationvan Pelt-Koops, J. C., Pett, H., Graumans, W., van der Vegte-Bolmer, M., van Gemert, G. J., Rottmann, M., Yeung, B. K. S., Diagana, T. T., & Sauerwein, R. W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06377-11 · Cited by 138
Pharmacokinetic Determinants of the Window of Selection for Antimalarial Drug Resistance
Stepniewska, K., & White, N. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00903-07 · Cited by 133
Primaquine for Prevention of Malaria in Travelers
Baird, J. K., Fryauff, D. J., & Hoffman, S. L. (2003) · Clinical Infectious Diseases · doi:10.1086/379714 · Cited by 116
A Research Agenda for Malaria Eradication: Health Systems and Operational Research
The malERA Consultative Group on Health Systems and Operational Research (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000397 · Cited by 111
Möhrle, J. J., Duparc, S., Siethoff, C., van Giersbergen, P. L. M., Craft, J. C., Arbe‐Barnes, S., Charman, S. A., Gutierrez, M., Wittlin, S., & Vennerstrom, J. L. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04368.x · Cited by 107
Self-citationA Research Agenda for Malaria Eradication: Modeling
The malERA Consultative Group on Modeling (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000403 · Cited by 105
A Research Agenda for Malaria Eradication: Basic Science and Enabling Technologies
The malERA Consultative Group on Basic Science and Enabling Technologies (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000399 · Cited by 102
Griffin, J. B., Lokomba, V., Landis, S. H., Thorp, J. M., Herring, A. H., Tshefu, A. K., Rogerson, S. J., & Meshnick, S. R. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-319 · Cited by 97
High-dose Primaquine Regimens against Relapse of Plasmodium vivax Malaria
Krudsood, S., Tangpukdee, N., Wilairatana, P., Phophak, N., Baird, J. K., Brittenham, G. M., & Looareesuwan, S. (2008) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2008.78.736 · Cited by 94
Valecha, N., Phyo, A. P., Mayxay, M., Newton, P. N., Krudsood, S., Keomany, S., Khanthavong, M., Pongvongsa, T., Ruangveerayuth, R., Uthaisil, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011880 · Cited by 93
van der Kolk, M., de Vlas, S. J., Saul, A. J., VEGTE-BOLMER, M. V. D., ELING, W., & SAUERWEIN, W. (2004) · Parasitology · doi:10.1017/s0031182004006067 · Cited by 92
Artemisinin resistance on the Thai–Cambodian border
Yeung, S., Socheat, D., Moorthy, V., & MILLS, A. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61856-0 · Cited by 74
Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets
Ding, X. C., Beck, H., & Raso, G. (2010) · Trends in Parasitology · doi:10.1016/j.pt.2010.11.006 · Cited by 74
Kern, S. E., Tiono, A. B., Makanga, M. M., Gbadoé, A. D., Premji, Z. G., Gaye, O., Sagara, I., Ubben, D., Cousin, M., Oladiran, F., et al. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-210 · Cited by 72
Ogutu, B. R., Tiono, A. B., Makanga, M. M., Premji, Z. G., Gbadoé, A. D., Ubben, D., Marrast, A. C., & Gaye, O. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-30 · Cited by 68
Cross-species regulation of malaria parasitaemia in the human host
Bruce, M. C., & Day, K. P. (2002) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(02)00348-x · Cited by 66
The Evolutionary Consequences of Blood-Stage Vaccination on the Rodent Malaria Plasmodium chabaudi
Barclay, V. C., Sim, D. G., Chan, B. H. K., Nell, L. A., Rabaa, M. A., Bell, A. S., Anders, R. F., & Read, A. F. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001368 · Cited by 63
Schlagenhauf, P., Blumentals, W. A., Suter, P., Regep, L., Vital-Durand, G., Schaerer, M. T., Boutros, M. S., Rhein, H.-G., & Adamcova, M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis215 · Cited by 57 · cited 1×
“Demand may increase if the medicine is shown to have benefit for the prevention of malaria in pregnancy [54].”
BackgroundMalaria drug resistance: new observations and developments
Sá, J. M., Chong, J. L., & Wellems, T. E. (2011) · Essays in Biochemistry · doi:10.1042/bse0510137 · Cited by 41
A Research Agenda for Malaria Eradication: Cross-Cutting Issues for Eradication
The malERA Consultative Group on Integration Strategies (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000404 · Cited by 37
Smithuis, F. M., van der Broek, I., Katterman, N., Kyaw, M. K., Brockman, A., Lwin, S., & White, N. J. (2004) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(03)00035-x · Cited by 25
Drug Discovery for Lower Respiratory Tract Infections
Craft, J. C. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733496-00366 · Cited by 1
Cited by
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
Self-citationThe medicinal chemistry of ferrocene and its derivatives
Patra, M., & Gasser, G. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0066 · Cited by 609
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
Self-citationNew developments in anti-malarial target candidate and product profiles
Burrows, J. N., Duparc, S., Gutteridge, W. E., Hooft van Huijsduijnen, R., Kaszubska, W., Macintyre, F., Mazzuri, S., Möhrle, J. J., & Wells, T. N. C. (2017) · Malaria Journal · doi:10.1186/s12936-016-1675-x · Cited by 520
Self-citationThe past, present and future of anti-malarial medicines
Tse, E. G., Korsik, M., & Todd, M. H. (2019) · Malaria Journal · doi:10.1186/s12936-019-2724-z · Cited by 471
Metadata
- Authors
- Burrows, J. N., Hooft van Huijsduijnen, R., Möhrle, J. J., Oeuvray, C., & Wells, T. N.
- Venue
- Malaria Journal
- Published
- 2013-06-06
- Volume
- 12
- Issue
- 1
- Pages
- 187-187
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W2154313767
- Cited by
- 282
- References
- 50
- FWCI
- 37.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.